Immunotherapy: A New Principle of Cancer Therapy
H. Kaur, R. Sodhi, A. Babu
{"title":"Immunotherapy: A New Principle of Cancer Therapy","authors":"H. Kaur, R. Sodhi, A. Babu","doi":"10.35652/igjps.2019.92s15","DOIUrl":null,"url":null,"abstract":"Immunotherapy, also called biologic therapy, is a type of cancer treatment that boosts the body’s natural defence systems to fight cancer. It uses substances made by the body or in laboratory to improve or restore immune system function. Earlier cancer treatment consisted of surgery, radiation, chemotherapy and horrmonal treatments. In recent years, immunotherapy has become an important therapeutic alternative, and is now the first choice in many cases. One of the greatest achievements with monoclonal antibodies is their use in human therapy. Surgery, chemotherapy and radiotherapy are not specifically directed to tumor cells and may also affect healthy tissue. Antibodies can provide specificity and lower toxicity, opening new therapeutic possibilities. The objective is for the antibody to act as a transporter for the cancer-killing agent, concentrating the agent directly in the cancer cell, with minimal damage to healthy cells. Although conjugated antibodies showed toxicity in the past, more recent approaches under development appear to decrease unwanted side effects. Drugs known as immune checkpoint inhibitors can physically block the checkpoint CTLA-4, a protein receptor which frees the immune system to attack the cancerous cells. A single T-cell can kill thousands of cancer cells. © 2019 iGlobal Research and Publishing Foundation. All rights reserved. Cite this article as: Kaur, H.; Sodhi, R.K.; babu, A. Immunotherapy: a new principle of cancer therapy. Indo Global J. Pharm. Sci., 2019; 9(2Suppl.): 117. DOI: http://doi.org/10.35652/IGJPS.2019.92S15 . Indo Global Journal of Pharmaceutical Sciences( ISSN 2249 1023; CODENIGJPAI; NLM ID: 101610675) indexed and abstracted in CrossRef (DOI Enabling), UGC CARE Journal List, EMBASE(Elsevier), National Library of Medicine (NLM) Catalog, ResearchGate, Publons, CAS (ACS), Index Copernicus, Google Scholar and many more. For further details, visit http://iglobaljournal.com This is a special issue as an outcome of ‘RAPSCON-2019’ sponsored by APTI and organized by Sri Sai College of Pharmacy, Manawala, Amritsar, Punjab, India. Relaxation offered in journal format.","PeriodicalId":13366,"journal":{"name":"Indo Global Journal of Pharmaceutical Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indo Global Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35652/igjps.2019.92s15","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Immunotherapy, also called biologic therapy, is a type of cancer treatment that boosts the body’s natural defence systems to fight cancer. It uses substances made by the body or in laboratory to improve or restore immune system function. Earlier cancer treatment consisted of surgery, radiation, chemotherapy and horrmonal treatments. In recent years, immunotherapy has become an important therapeutic alternative, and is now the first choice in many cases. One of the greatest achievements with monoclonal antibodies is their use in human therapy. Surgery, chemotherapy and radiotherapy are not specifically directed to tumor cells and may also affect healthy tissue. Antibodies can provide specificity and lower toxicity, opening new therapeutic possibilities. The objective is for the antibody to act as a transporter for the cancer-killing agent, concentrating the agent directly in the cancer cell, with minimal damage to healthy cells. Although conjugated antibodies showed toxicity in the past, more recent approaches under development appear to decrease unwanted side effects. Drugs known as immune checkpoint inhibitors can physically block the checkpoint CTLA-4, a protein receptor which frees the immune system to attack the cancerous cells. A single T-cell can kill thousands of cancer cells. © 2019 iGlobal Research and Publishing Foundation. All rights reserved. Cite this article as: Kaur, H.; Sodhi, R.K.; babu, A. Immunotherapy: a new principle of cancer therapy. Indo Global J. Pharm. Sci., 2019; 9(2Suppl.): 117. DOI: http://doi.org/10.35652/IGJPS.2019.92S15 . Indo Global Journal of Pharmaceutical Sciences( ISSN 2249 1023; CODENIGJPAI; NLM ID: 101610675) indexed and abstracted in CrossRef (DOI Enabling), UGC CARE Journal List, EMBASE(Elsevier), National Library of Medicine (NLM) Catalog, ResearchGate, Publons, CAS (ACS), Index Copernicus, Google Scholar and many more. For further details, visit http://iglobaljournal.com This is a special issue as an outcome of ‘RAPSCON-2019’ sponsored by APTI and organized by Sri Sai College of Pharmacy, Manawala, Amritsar, Punjab, India. Relaxation offered in journal format.
免疫疗法:癌症治疗的新原则
免疫疗法,也被称为生物疗法,是一种增强人体自然防御系统来对抗癌症的癌症治疗方法。它使用人体或实验室制造的物质来改善或恢复免疫系统功能。早期的癌症治疗包括手术、放疗、化疗和激素治疗。近年来,免疫疗法已成为一种重要的治疗选择,现在是许多病例的首选。单克隆抗体最大的成就之一是它们在人类治疗中的应用。手术、化疗和放疗不是专门针对肿瘤细胞的,也可能影响健康组织。抗体可以提供特异性和低毒性,开辟新的治疗可能性。目的是让抗体充当癌症杀伤剂的转运体,直接将药物集中在癌细胞中,对健康细胞的损害最小。虽然过去偶联抗体显示出毒性,但最近正在开发的方法似乎可以减少不必要的副作用。被称为免疫检查点抑制剂的药物可以物理地阻断检查点CTLA-4, CTLA-4是一种蛋白质受体,可以释放免疫系统来攻击癌细胞。一个t细胞可以杀死数千个癌细胞。©2019 igglobal研究与出版基金会。版权所有。引用本文如下:Kaur, H.;位址,上面;免疫疗法:癌症治疗的新原理。印度国际制药公司。科学。, 2019;9(2生理):117。DOI: http://doi.org/10.35652/IGJPS.2019.92S15。印度全球药物科学杂志(ISSN 2249 1023;CODENIGJPAI;NLM ID: 101610675)在CrossRef (DOI Enabling), UGC CARE Journal List, EMBASE(Elsevier), National Library of Medicine (NLM) Catalog, ResearchGate, Publons, CAS (ACS), Index哥白尼,Google Scholar等中索引和摘要。欲了解更多详情,请访问http://iglobaljournal.com这是由APTI赞助,印度旁遮普阿姆利则马纳瓦拉斯里赛药学院组织的“RAPSCON-2019”的特刊。以日志形式提供放松。
本文章由计算机程序翻译,如有差异,请以英文原文为准。